Key Points
- Director Joseph Capper purchased 25,000 TELA Bio shares at an average price of $1.22, investing $30,500 and increasing his direct ownership by 16.15% to 179,827 shares.
- TELA Bio’s latest quarterly results fell short of expectations, with an EPS loss of $0.20 versus the $0.17 expected and revenue of $19.29 million versus the $20.01 million consensus estimate.
- Analyst sentiment remains mixed, resulting in a consensus “Hold” rating and a $2.20 target price; institutional investors own approximately 94.35% of the company.
TELA Bio, Inc. (NASDAQ:TELA - Get Free Report) Director Joseph Capper acquired 25,000 shares of TELA Bio stock in a transaction that occurred on Thursday, September 17th. The stock was acquired at an average cost of $1.22 per share, with a total value of $30,500.00. Following the purchase, the director directly owned 179,827 shares of the company's stock, valued at $219,388.94. This represents a 16.15% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
TELA Bio Stock Down 3.1%
TELA Bio stock opened at $1.25 on Friday. The business has a fifty day moving average of $0.79 and a two-hundred day moving average of $0.80. The company has a quick ratio of 2.38, a current ratio of 2.99 and a debt-to-equity ratio of 8.82. The firm has a market cap of $56.42 million, a P/E ratio of -1.62 and a beta of 1.36. TELA Bio, Inc. has a twelve month low of $0.50 and a twelve month high of $1.69.
TELA Bio (NASDAQ:TELA - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03). The company had revenue of $19.29 million during the quarter, compared to analysts' expectations of $20.01 million. TELA Bio had a negative net margin of 51.53% and a negative return on equity of 1,320.81%. On average, analysts forecast that TELA Bio, Inc. will post -0.76 earnings per share for the current fiscal year.
Analyst Ratings Changes
Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of TELA Bio in a report on Friday, July 17th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus target price of $2.20.
Read Our Latest Stock Report on TELA Bio
Institutional Investors Weigh In On TELA Bio
Large investors have recently made changes to their positions in the stock. Nantahala Capital Management LLC purchased a new position in TELA Bio during the 2nd quarter worth approximately $4,420,586. Stonepine Capital Management LLC purchased a new position in TELA Bio during the second quarter worth approximately $1,996,820. BlackRock Inc. purchased a new position in TELA Bio during the second quarter worth approximately $281,000. UP Strategic Wealth Investment Advisors LLC acquired a new stake in TELA Bio in the second quarter valued at approximately $91,000. Finally, Perkins Capital Management Inc. increased its position in shares of TELA Bio by 1.5% in the first quarter. Perkins Capital Management Inc. now owns 1,418,328 shares of the company's stock valued at $879,000 after buying an additional 20,910 shares in the last quarter. 94.35% of the stock is owned by hedge funds and other institutional investors.
TELA Bio Company Profile
(
Get Free Report)
TELA Bio, Inc is a medical technology company focused on developing and commercializing implantable products for soft-tissue reconstruction. Its products are designed to support the repair and reinforcement of damaged or weakened soft tissue, including tissue affected by hernias, abdominal wall defects and other reconstructive procedures.
The company's principal product platform is OviTex Reinforced Tissue Matrix, a family of biologic implants that combines extracellular matrix tissue with a polymer reinforcement structure.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
